Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,447 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colorectal Cancer Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?

NCT01035775
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Polyps
Interventions
Inspection during insertion, Inspection during withdrawal
Procedure
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 25, 2026, 10:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

NCT05257057
View directory record Official record
Conditions
Lynch Syndrome, Endometrial Cancer, Endometrial Hyperplasia, Mismatch Repair Deficiency, Microsatellite Instability
Interventions
Immunohistochemical staining
Diagnostic Test
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional

A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

NCT00034502
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ALIMTA, irinotecan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Wichita, Kansas • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00004095
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 25, 2026, 10:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Uncertain Genetic Test Results for Lynch Syndrome

NCT01646112
View directory record Official record
Conditions
HNPCC
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

NCT00028405
View directory record Official record
Conditions
Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions
LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
Drug · Device
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856
View directory record Official record
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer
Interventions
VVD-133214, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Tucson, Arizona • Duarte, California • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Exploratory Study Of The ERCC-1 Gene

NCT00846482
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Oxaliplatin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

NCT07224841
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

NCT02033551
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions
Veliparib, Carboplatin, Paclitaxel, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional Results available

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

NCT04406857
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Capecitabine, Radiation Therapy, Ropidoxuridine
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Lexington, Kentucky • Columbus, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver

NCT00089401
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
isolated perfusion, melphalan, conventional surgery
Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017
View directory record Official record
Conditions
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions
Pixatimod, Nivolumab, Cyclophosphamide (low dose)
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

NCT05589597
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
EO4010
Drug
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

NCT00028496
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

NCT03693846
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

NCT05243862
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
PolyPEPI1018, Atezolizumab
Drug
Lead sponsor
Treos Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Precise Oncology Interventions in Nutrition and Training (OnPoint)

NCT06534918
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma
Interventions
Fitbit, Nutrition Course: Group Sessions, Physical Activity Program: Group Sessions, Nutrition Course: One on One Sessions with Registered Dietitian, Physical Activity Program: One on One Sessions with an Exercise Physiologist, Nutrition and Physical Activity Prescription
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Not yet recruiting Phase 3 Interventional

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

NCT02448173
View directory record Official record
Conditions
Stage II Colon Cancer
Interventions
OncoVAX and Surgery, Surgery
Biological · Procedure
Lead sponsor
Vaccinogen Inc
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Not listed Phase 4 Interventional

Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery

NCT02958566
View directory record Official record
Conditions
Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Interventions
Acetaminophen, Gabapentin, Orphenadrine, Lidocaine, Marcaine, Ketamine, Methadone, Tramadol, Ketorolac, Morphine Sulfate, Fentanyl, Dilaudid, Hydrocodone-Acetaminophen Tab 5-325 MG, HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
Drug
Lead sponsor
University of Illinois College of Medicine at Peoria
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 25, 2026, 10:14 PM EDT
Completed No phase listed Observational

The Identification of Prognostic Factors of Late Stage Disease, Particularly Those That Are Modifiable, That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.

NCT00007618
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2011 · Synced Oct 25, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

NCT01095523
View directory record Official record
Conditions
Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions
Laparotomy+ HIPEC +/- CRS
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 10:14 PM EDT